Compare IDEXX Laboratories, Inc. (IDXX) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Palo Alto Networks Inc — how do they compare? IDEXX Laboratories, Inc. trades at $553.81 (market cap $44.48B), while Palo Alto Networks Inc trades at $338.69 (market cap $284.16B). The key difference: Palo Alto Networks Inc is far larger — about 6.4× IDEXX Laboratories, Inc.'s market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | PANW | |
|---|---|---|
Market Cap | $44.48B | $284.16B |
Sector | Health | Technology |
52-Week High | $766.68 | $358.68 |
52-Week Low | $520.87 | $141.67 |
Enterprise Value | $45.38B | $283.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Palo Alto Networks (PANW) trades at $353.85, down 1.35% on the day but showing strong bullish momentum with shares roughly doubling over three months. The stock exhibits robust fundamentals with consistent earnings beats, revenue growth to $9.22B in 2025, and a high gross margin of 71.94%. Technical indicators signal a bullish trend, supported by positive moving averages, though RSI levels suggest potential overbought conditions near-term.
Outlook remains positive driven by AI-driven cybersecurity demand and platformization strategy, but high valuation ratios (P/E 311.9, P/S 24.9) pose risks. Analyst consensus is strongly bullish (74% Buy ratings) with a $339.56 price target, though competition and integration costs are key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
